^
Association details:
| Biomarker: | FGF10 amplification |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | Pemazyre (pemigatinib) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Interim results of fight-201, a phase II, open-label, multicenter study of INCB054828 in patients (pts) with metastatic or surgically unresectable urothelial carcinoma (UC) harboring fibroblast growth factor (FGF)/FGF receptor (FGFR) genetic alterations (GA)
Excerpt:
This study (NCT02872714) is enrolling pts with metastatic or unresectable UC who failed ≥ 1 therapy or are platinum ineligible and have FGFR3 mutations/fusions (cohort A, n = 100) or other FGF/FGFR GAs (cohort B, n = 40)...In cohort B, 1 pt with FGF10 amplification had an unconfirmed PR.
DOI:
https://doi.org/10.1093/annonc/mdy283.109
Trial ID:
